Brokerages predict that Avrobio Inc (NASDAQ:AVRO) will announce earnings of ($0.58) per share for the current quarter, Zacks reports. Zero analysts have issued estimates for Avrobio’s earnings. The lowest EPS estimate is ($0.69) and the highest is ($0.41). The company is scheduled to report its next quarterly earnings results on Tuesday, February 12th.
On average, analysts expect that Avrobio will report full-year earnings of ($3.18) per share for the current year, with EPS estimates ranging from ($4.57) to ($1.82). For the next fiscal year, analysts forecast that the business will report earnings of ($2.24) per share, with EPS estimates ranging from ($2.93) to ($1.28). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research firms that follow Avrobio.
Avrobio (NASDAQ:AVRO) last announced its quarterly earnings data on Tuesday, November 13th. The company reported ($0.49) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.91) by $0.42.
Institutional investors and hedge funds have recently bought and sold shares of the business. American International Group Inc. acquired a new stake in shares of Avrobio during the third quarter worth $210,000. Rhumbline Advisers acquired a new stake in shares of Avrobio during the third quarter worth $235,000. Man Group plc acquired a new stake in shares of Avrobio during the third quarter worth $329,000. TD Asset Management Inc. acquired a new stake in shares of Avrobio during the second quarter worth $217,000. Finally, MetLife Investment Advisors LLC acquired a new stake in shares of Avrobio during the third quarter worth $410,000. Institutional investors own 67.57% of the company’s stock.
NASDAQ AVRO traded up $1.10 during trading hours on Friday, hitting $26.79. The company’s stock had a trading volume of 80,748 shares, compared to its average volume of 59,340. Avrobio has a twelve month low of $20.30 and a twelve month high of $53.70.
AVROBIO, Inc, a clinical stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose. The company's gene therapies employ hematopoietic stem cells that are extracted from the patient and modified with lentiviral vectors to insert a functional copy of the gene that is defective in the target disease.
Featured Article: How to interpret a stock’s beta number
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Avrobio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avrobio and related companies with MarketBeat.com's FREE daily email newsletter.